Fig. 10From: Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteineSUMMARY NRAS. NRAS-mutant cell hypoxic susceptibility to Prima-1 ± 3-BrPA is not reversed by 2 mM NAC. Hypoxic resistance of KRAS mutant cells to 3-BrPA correlates with greater attenuation of Prima-1 toxicity by 2 mM NACBack to article page